Tag: #DirectActingAntivirals

Introduction Chronic Hepatitis C Virus (HCV) infection remains a significant cause of liver related morbidity worldwide, often progressing silently to cirrhosis or hepatocellular carcinoma if left untreated. Recent advances in direct-acting antivirals (DAAs) have transformed HCV management, offering shorter treatment durations with high cure rates. A growing body of evidence now supports 8-week antiviral regimens…